# A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

> **NCT05864924** · PHASE1 · COMPLETED · sponsor: **BioSyngen Pte Ltd** · enrollment: 14 (actual)

## Conditions studied

- EBV-positive Nasopharyngeal Carcinoma

## Interventions

- **BIOLOGICAL:** Cohort A: 3.0x10^6 CAR-T cells/kg
- **BIOLOGICAL:** Cohort B: 9.0x10^6CAR-T cells/kg
- **BIOLOGICAL:** Cohort C:1.5x10^7 CAR-T cells /kg

## Key facts

- **NCT ID:** NCT05864924
- **Lead sponsor:** BioSyngen Pte Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-10
- **Primary completion:** 2024-04-26
- **Final completion:** 2024-04-26
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05864924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05864924, "A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05864924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*